CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .
Use of “spydergrams” to present and interpret SF-36 health-related quality of life data across rheumatic diseases
The Medical Outcomes Study Short Form-36 ( SF-36 ) is a generic measure of health-related quality of life ( HRQOL ) , vali date d and cross-culturally translated , which has been extensively utilised in rheumatology . In r and omised controlled trials and observational studies , SF-36 provides rich data regarding HRQOL ; but as typically portrayed , patterns of disease and treatment-associated effects can be difficult to discern . “ Spydergrams ” offer a simplified means to visualise complex results across all domains of SF-36 in a single figure : depicting disease and population -specific patterns of decrements in HRQOL compared with age and gender-matched normative data , as well as providing a tool for interpreting complex treatment-associated or longitudinal changes . Utilising spydergrams as a st and ard format to illustrate and report changes in SF-36 across different rheumatic diseases can greatly facilitate analyses and interpretations of clinical trial results , as well as providing patients an accessible means to compare baseline scores and treatment-associated improvements with normative data from individuals without arthritis . Furthermore , SF-6D utility scores based on mean changes across all eight domains of SF-36 are suggested as a quantitative means of summarising changes illustrated by spydergrams , offering a universal metric for cost-effectiveness analyses of therapeutic interventions
CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .